Lv2
110 积分 2022-06-02 加入
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
1天前
已完结
Novel strategies to manage CAR-T cell toxicity
1天前
已完结
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
1个月前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
2个月前
已完结
Time to sustained responder status in patients with focal seizures treated with adjunctive eslicarbazepine acetate
2个月前
已关闭
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies
3个月前
已完结
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
3个月前
已完结
Thirty years of intravenous thrombolysis for acute ischemic stroke: Historical perspectives, evidence from randomized trials, and emerging directions
5个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
10个月前
已完结
皖公网安备34019202002308
